Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplusâ„¢ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases
Secarna's LNAplusâ„¢ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory...

















